Ontology highlight
ABSTRACT:
SUBMITTER: Devlin R
PROVIDER: S-EPMC6142493 | biostudies-literature | 2016 Dec
REPOSITORIES: biostudies-literature
Hematology. American Society of Hematology. Education Program 20161201 1
Hematopoietic cell transplantation (HCT) is the only curative therapeutic modality for myelofibrosis (MF) at present. The optimal timing of HCT is not known in the presence of wider availability of less risky nontransplant therapies such as JAK 1/2 inhibitors. Careful review of patient, disease, and transplant-related factors is required in the appropriate selection of HCT vs the best available nontransplant therapies. We highlight some of the relevant issues and positioning of HCT in light of e ...[more]